Note: Ingredients listed on restricted chemical lists
EC/CAS
210-834-9/624-18-0
Name of the chemical
p-Phenylenediamine dihydrochloride
Concentration
<=100%
General Information
Version
6.3
Revision date
2020-09-18
Product name
1,4-Phenylenediamine dihydrochloride
CAS No.
624-18-0
REACH No
A
Emergency telephone
800-424-9300, +1-703- 527-3887
Icons in SDS
Company Information
company name
Sigma-Aldrich Inc
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H301, H311, H317, H319, H331, H410
Hazard statements
Code
Statements
H301
Toxic if swallowed
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008] Classification of the substance or mixture
Signal word
Danger
Hazard statements
H301 Toxic if swallowed. H311 Toxic in contact with skin. H317 May cause an allergic skin reaction. H319 Causes serious eye irritation. H331 Toxic if inhaled. H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements
P261 Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing. P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER/ doctor. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P311 Call a POISON CENTER/ doctor.
Supplemental label elements
none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Acute toxicity, Inhalation (Category 3), H331 Acute toxicity, Dermal (Category 3), H311 Acute toxicity, Oral (Category 3), H301 Eye irritation (Category 2), H319 Skin sensitization (Category 1), H317 Short-term (acute) aquatic hazard (Category 1), H400 Long-term (chronic) aquatic hazard (Category 1), H410 For the full text of the H-Statements mentioned in this Section, see Section 16.